Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS
CompanyDrug

Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS

Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease
CompanyDrug

Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease

Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP
Others

Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP

Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia
CompanyDeals

Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia

Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone
CompanyDrug

Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone

Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
CompanyDrug

Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402

JCBio & MGI Launch Korea’s First DCS Lab to Accelerate Multi‑Omics Innovation
CompanyDeals

JCBio & MGI Launch Korea’s First DCS Lab to Accelerate Multi‑Omics Innovation

IVD Medical Acquires 20 % of GoFintech in HK$3.14 B Deal
CompanyDeals

IVD Medical Acquires 20 % of GoFintech in HK$3.14 B Deal

Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
CompanyDeals

Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor

Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria
CompanyDrug

Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria

Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment
CompanyDrug

Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment

Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
CompanyDrug

Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors